Imidazopyridinyl benzamide mitotic kinesin inhibitors
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
1. A compound that is N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide.
2. A composition comprising at least one pharmaceutical excipient and a compound according to claim 1 .
3. The composition of claim 2 wherein the composition is formulated for administration by a route chosen from oral, subcutaneous, intravenous, intranasal, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal, and intraocular.
4. The composition of claim 3 wherein the composition is formulated for oral administration.
5. The composition of claim 4 wherein the composition is formulated as a tablet, capsule, or liquid.
6. The composition of claim 4 wherein the at least one pharmaceutical excipient is selected from diluents, binders, glidants, lubricants, disintegrants, colors, flavors, sweetening agents, polymers, waxes and other solubility-retarding materials.
7. The composition of claim 3 wherein the composition is formulated for intravenous administration.
8. The composition of claim 7 wherein the at least one pharmaceutical excipient comprises a sterile solution of sugars, amino acids or electrolytes.
9. The composition of claim 7 wherein the at least one pharmaceutical excipient is water for injection USP.
10. The composition of claim 2 wherein the composition is formulated for parenteral administration.
11. The composition of claim 10 wherein the at least one pharmaceutical excipient comprises a sterile solution of sugars, amino acids or electrolytes.
12. The composition of claim 10 wherein the at least one pharmaceutical excipient is water for injection USP.
13. A compound of the formula
14. A composition comprising at least one pharmaceutical excipient and a compound according to claim 13 .
15. The composition of claim 14 wherein the composition is formulated for administration by a route chosen from oral, subcutaneous, intravenous, intranasal, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal, and intraocular.
16. The composition of claim 15 wherein the composition is formulated for oral administration.
17. The composition of claim 16 wherein the composition is formulated as a tablet, capsule, or liquid.
18. The composition of claim 16 wherein the at least one pharmaceutical excipient is selected from diluents, binders, glidants, lubricants, disintegrants, colors, flavors, sweetening agents, polymers, waxes and other solubility-retarding materials.
19. The composition of claim 15 wherein the composition is formulated for intravenous administration.
20. The composition of claim 19 wherein the at least one pharmaceutical excipient comprises a sterile solution of sugars, amino acids or electrolytes.
21. The composition of claim 19 wherein the at least one pharmaceutical excipient is water for injection USP.
22. The composition of claim 14 wherein the composition is formulated for parenteral administration.
23. The composition of claim 22 wherein the at least one pharmaceutical excipient comprises a sterile solution of sugars, amino acids or electrolytes.
24. The composition of claim 22 wherein the at least one pharmaceutical excipient is water for injection USP.